Centanafadine SR

DRUG4 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

Attention Deficit DisorderAttention Deficit Hyperactivity DisorderHealthy Volunteers

Phase 1

A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine

CompletedNCT07465731

Otsuka Pharmaceutical Development & Commercialization, Inc.Healthy Volunteers

Start: 2022-10-27End: 2023-03-26Updated: 2026-03-12

Phase 3

A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

CompletedNCT03605836

Otsuka Pharmaceutical Development & Commercialization, Inc.Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder

Start: 2019-01-16End: 2020-05-14Updated: 2021-10-18

A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder

CompletedNCT03605680

Otsuka Pharmaceutical Development & Commercialization, Inc.Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder

Start: 2019-01-16End: 2020-04-11Updated: 2022-03-15

A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

CompletedNCT03605849

Otsuka Pharmaceutical Development & Commercialization, Inc.Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder

Start: 2019-02-14End: 2021-09-07Updated: 2024-10-01

Related Papers

A Matching-Adjusted Indirect Comparison (MAIC) of Centanafadine versus Methylphenidate Hydrochloride in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD): Short-Term Safety and Efficacy Outcomes: Comparaison indirecte ajustée par appariement (MAIC) entre centanafadine et le chlorhydrate de méthylphénidate chez les adultes atteints d’un trouble déficitaire de l'attention avec ou sans hyperactivité (TDAH) : Résultats en matière d’innocuité et d’efficacité à court terme

The Canadian Journal of Psychiatry2025-06-021 citations

Centanafadine Sustained Release Is Efficacious in Patients with Adult ADHD, Regardless of Their Treatment History

CNS Spectrums2024-10-01

52-Week Open-Label Safety and Tolerability Trial of Centanafadine Sustained Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

CNS Spectrums2024-10-01

Centanafadine Sustained Release Is Efficacious in the Treatment of Adult ADHD Across Disease Severities

CNS Spectrums2024-10-01

A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy

Journal of Comparative Effectiveness Research2024-08-122 citations

Assessment of centanafadine in adults with ADHD: a matching adjusted indirect comparison versus methylphenidate hydrochloride extended release (Concerta).

2024-07-103 citations

Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release

Journal of Managed Care & Specialty Pharmacy2024-06-017 citations